ABVC BioPharma Statistics
Total Valuation
ABVC BioPharma has a market cap or net worth of $8.28 million. The enterprise value is $10.70 million.
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024, before market open.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ABVC BioPharma has 11.99 million shares outstanding. The number of shares has increased by 138.19% in one year.
| Shares Outstanding | 11.99M |
| Shares Change (YoY) | +138.19% |
| Shares Change (QoQ) | +16.28% |
| Owned by Insiders (%) | 23.25% |
| Owned by Institutions (%) | 1.84% |
| Float | 9.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 41.95 |
| Forward PS | n/a |
| PB Ratio | 1.01 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 78.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.33, with a Debt / Equity ratio of 0.35.
| Current Ratio | 0.33 |
| Quick Ratio | 0.03 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.61 |
Financial Efficiency
Return on equity (ROE) is -320.36% and return on invested capital (ROIC) is -66.53%.
| Return on Equity (ROE) | -320.36% |
| Return on Assets (ROA) | -44.55% |
| Return on Capital (ROIC) | -66.53% |
| Revenue Per Employee | $7,179 |
| Profits Per Employee | -$598,635 |
| Employee Count | 19 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ABVC BioPharma has paid $63,417 in taxes.
| Income Tax | 63,417 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.89% in the last 52 weeks. The beta is 0.81, so ABVC BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | -42.89% |
| 50-Day Moving Average | 0.64 |
| 200-Day Moving Average | 0.94 |
| Relative Strength Index (RSI) | 56.90 |
| Average Volume (20 Days) | 309,583 |
Short Selling Information
The latest short interest is 138,130, so 1.15% of the outstanding shares have been sold short.
| Short Interest | 138,130 |
| Short Previous Month | 131,680 |
| Short % of Shares Out | 1.15% |
| Short % of Float | 1.51% |
| Short Ratio (days to cover) | 0.88 |
Income Statement
In the last 12 months, ABVC BioPharma had revenue of $136,396 and -$11.37 million in losses. Loss per share was -$1.43.
| Revenue | 136,396 |
| Gross Profit | -32,891 |
| Operating Income | -8.54M |
| Pretax Income | -12.37M |
| Net Income | -11.37M |
| EBITDA | -8.51M |
| EBIT | -8.54M |
| Loss Per Share | -$1.43 |
Full Income StatementBalance Sheet
The company has $199,979 in cash and $2.73 million in debt, giving a net cash position of -$2.53 million or -$0.21 per share.
| Cash & Cash Equivalents | 199,979 |
| Total Debt | 2.73M |
| Net Cash | -2.53M |
| Net Cash Per Share | -$0.21 |
| Equity (Book Value) | 7.83M |
| Book Value Per Share | 0.71 |
| Working Capital | -4.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$3.33 million and capital expenditures -$21,201, giving a free cash flow of -$3.35 million.
| Operating Cash Flow | -3.33M |
| Capital Expenditures | -21,201 |
| Free Cash Flow | -3.35M |
| FCF Per Share | -$0.28 |
Full Cash Flow StatementMargins
| Gross Margin | -24.11% |
| Operating Margin | -6,259.36% |
| Pretax Margin | -8,715.89% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -12,745.24% |